Second Opinions Improve ADHD Prescribing in a Medicaid-Insured Community Population: "The review process resulted in a savings of $1.2 million, with 538 fewer patients exceeding safety thresholds. This was a 10:1 return over administrative costs; however, the overall Medicaid expenditures for ADHD medication still increased because of higher unit costs and the preferential use by clinicians of newer brands entering the market."
'via Blog this'
No comments:
Post a Comment